Researchers

KUDO Masatoshi
Senior Administrator
Faculty Department of Medicine / Graduate School of Medical Sciences
Researchmap https://researchmap.jp/m-kudo

Education and Career

Academic & Professional Experience

  • Apr. 1999 - Today , Kindai University Faculty of Medicine Professor and Chairman

Research Activities

Research Areas

  • Life sciences, Gastroenterology
  • Life sciences, Medical systems
  • Life sciences, Tumor diagnostics and therapeutics

Research Interests

Immune checkpoint inhibitor, Immunotherapy, Molecular targeted therapy, Transarterial chemoembolization (TACE), Conrast-ehnaced ultrasonogaraphy, Radiofreuqency ablation (RFA), Hepatocellular carcinoma, 肝腫瘍の画像診断, EOB-MRI, 肝動注化学療法, 血管新生阻害治療

Published Papers

  1. Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents.
    Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    Hepatobiliary surgery and nutrition  9  (6)  , 777-779, Dec. 2020  , Refereed
  2. Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.
    Baek-Yeol Ryoo; Philippe Merle; Amit S Kulkarni; Ann-Lii Cheng; Mohamed Bouattour; Ho Yeong Lim; Valeriy Breder; Julien Edeline; Yee Chao; Sadahisa Ogasawara; Thomas Yau; Marcelo Garrido; Stephen L Chan; Bruno Daniele; Josephine M Norquist; Erluo Chen; Abby B Siegel; Andrew X Zhu; Richard S Finn; Masatoshi Kudo
    Cancer  24, Nov. 2020 
  3. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.
    Maria Reig; Peter R Galle; Masatoshi Kudo; Richard Finn; Josep M Llovet; Andrea L Metti; William R Schelman; Kun Liang; Chunxiao Wang; Ryan C Widau; Paolo Abada; Andrew X Zhu
    Liver international : official journal of the International Association for the Study of the Liver  14, Nov. 2020 

MORE

Books etc

  1. ラムシルマブによる肝細胞癌治療 , 小川 力, 筒井朱美, 永野拓也, 高口浩一, 谷 丈二, 森下朝洋, 正木 勉, 守屋昭男, 出口章広,工藤正俊 , 香川県下におけるラムシルマブの初期使用経験、pp211-215 , 香川県下におけるラムシルマブの初期使用経験、pp211-215 , アークメディア, 東京 , 2020
  2. ラムシルマブによる肝細胞癌治療 , 上嶋一臣,工藤正俊 , 肝細胞癌におけるラムシルマブの有害事象とその対策、pp124-129 , 肝細胞癌におけるラムシルマブの有害事象とその対策、pp124-129 , アークメディア, 東京 , 2020
  3. ラムシルマブによる肝細胞癌治療 , 小川 力,工藤正俊 , レンバチニブの二次治療としてラムシルマブは効果が期待できるか、pp119-123 , レンバチニブの二次治療としてラムシルマブは効果が期待できるか、pp119-123 , アークメディア, 東京 , 2020

MORE

Conference Activities & Talks

  1. KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation , Vogel A; Zhu AX; Cheng AL; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Kudo M , SIR 2021 congress , 20, Mar. 2021
  2. KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation , Uppot RN; Kudo M; Zhu AX; Cheng AL; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Vogel A , SIO 2021 congress , 3, Feb. 2021
  3. Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study , Edeline J; Cattan S; Merle P; Daniele B; Chan SL; Yau T; Bouattour M; Lim HY; Chao Y; Knox J; Ogasawara S; Garrido M; Cheng AL; Zhu AX; Finn RS; Siegel AB; Rahman A; Liu CC; Kudo M , Gastrointestinal Cancers Symposium (ASCO-GI 2021) (Virtual) , 15, Jan. 2021

MORE

MISC

  1. 【なんじゃこりゃ?part2】咽頭・食道 周囲に隆起を伴う陥凹性病変 , 高島 耕太; 松井 繁長; 工藤 正俊 , 消化器内視鏡 , 32 , 10 , 1405 , 1406 , Oct. 2020
  2. 【なんじゃこりゃ?part2】胃 発赤調の小さな隆起性病変 , 松井 繁長; 樫田 博史; 工藤 正俊 , 消化器内視鏡 , 32 , 10 , 1473 , 1474 , Oct. 2020
  3. 【なんじゃこりゃ?part2】胃 巨大で多発した胃ポリープ , 松井 繁長; 樫田 博史; 工藤 正俊 , 消化器内視鏡 , 32 , 10 , 1495 , 1496 , Oct. 2020

MORE

Awards & Honors

  1. Dec. 2018, Desai Memorial Lecture Award from Education Universe and Care Foundation
  2. Dec. 2018, SGHがん特別賞
  3. Oct. 2018, 台湾超音波医学会名誉会員賞(TSUM Honorary Member Award)

MORE